IL5 and asthma: A mouse asthma model was given oral/pulmonary administration of AG nanoformulation, and the bioavailability of the drug was greatly enhanced, as was the release of inflammatory factors (such as IL-4, IL-5 and IL-13), which were also significantly reduced.